TGase Protein Labeling Kits

Substrate Finder Kit



Order
Quantity
Price
Status
1 Kit 390 € available


Documents
Art. No. L001
Background info Transglutaminase labeling requires substrate sequences on the target protein surface, which are in general not abundant on proteins.
Therefore in a first step the target protein has to be analyzed for its transglutaminase substrate properties, which is perfomed using the Substrate Finder Kit.
Description Substrate Finder Kit (L001) allows you to prepare 4 reactions with your target protein and 1 control reaction testing for lysine substrates (Lys Labeling) as well as 4 with your target protein reactions and 1 control reaction testing for glutamine substrates labeling (Gln Labeling).

Transglutaminase Substrate Finder Kit L001 Zedira
Reagents in the kit MTG    Microbial Transglutaminase
LB    MTG-Labeling Buffer
CK    Lys-substrate control Protein
SK    ZQG-CAD-DNS
CQ    Gln-substrate control Protein
SQ    KxD
Application Assay for determination of protein's MTG substrate properties
Intended use The Substrate Finder Kit (L001) will determine your target protein’s transglutaminase substrate properties. Your target protein may either contain lysine substrates, glutamine substrates or both. It may also be in-accessible for transglutaminase-labeling.
Storage Store kit at 2 - 8°C. It is stable up to the expiry date stated on the label of the box. Do not use kit beyond its expiry date.
Store MTG at -20°C!

Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy